FibroGen Inc. (NASDAQ:FGEN) finished Wednesday with a subtraction of -$0.07 to close at $1.37, a downside of -4.86 percent. An average of 4,485,640 shares of common stock have been traded in the last five days. There was a fall of -$0.5300 in the past week, and it reached a new high 22 times over the past 12 months. The last 20 days have seen an average of 3,546,500 shares traded, while the 50-day average volume stands at 3,648,728.
FGEN stock has decreased by -49.82% in the last month. The company shares reached their 1-month lowest point of $1.2550 on 08/09/23. With the stock rallying to its 52-week high on 02/03/23, shares of the company touched a low of $1.41 and a high of $25.69 in 52 weeks. It has reached a new high 10 times so far this year and lost -91.45% or -$14.6500 in price. In spite of this, the price is down -94.67% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
FGEN stock investors should be aware that FibroGen Inc. (FGEN) stock had its last reported insider trading activity 6 days ago on Aug 04. In this transaction, the insider spent $3,820. Director, Henderson Jeffrey William, disposed of 2,000 shares at a price of $2.69 on Jul 11. The insider now owns more than $5,380 worth of shares. Prior to that, Chief Executive Officer Conterno Enrique A went on to Sale 1,880 shares at $2.80 each on Jul 07. An amount of $5,264 was transacted.
Valuation Metrics
FibroGen Inc. (FGEN) stock’s beta is 0.52. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 1.13.
Financial Health
The quick ratio of FibroGen Inc. for the three months ended June 29 was 1.50, and the current ratio was 1.70, indicating that the company is able to meet its debt obligations. FibroGen Inc.’s EBITDA margin for the year ending June 29 is -206.36%. Its gross profit as reported stood at $120.45 million compared to revenue of $140.73 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, FibroGen Inc.’s return on assets was -50.30%.
Earnings Surprise
For the three-month period that ended June 29, FibroGen Inc. had $183.13 million in cash and short-term investments compared to $71.41 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$87.68 million in the quarter, while revenues of -$76.71 million were grew 17.18%. The analyst consensus anticipated FibroGen Inc.’s latest quarter earnings to come in at -$0.7 per share, but it turned out to be -$0.9, a -28.60% surprise. For the quarter, EBITDA amounted to -$86.46 million. At the end of the quarter ending June 29, FibroGen Inc.’s stock balance sheet showed total liabilities of 596.91 million. Shareholders own equity worth $98.21 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at FibroGen Inc. (FGEN) price momentum. RSI 9-day as of the close on 09 August was 13.10%, suggesting the stock is oversold, with historical volatility in this time frame at 117.43%.
As of today, FGEN’s price is $1.6740 -27.89% or -$0.5300 from its 5-day moving average. FGEN is currently trading -48.88% lower than its 20-day SMA and -93.22% lower than its 100-day SMA. However, the stock’s current price level is -91.80% below the SMA50 and -91.14% below the SMA200.
The stochastic %K and %D were 5.60% and 5.72%, respectively, and the average true range (ATR) was 0.2259. With the 14-day stochastic at 11.33% and the average true range at 0.3424, the RSI (14) stands at 14.98%. The stock has reached -0.2789 on the 9-day MACD Oscillator while the 14-day reading was at -0.3390.
Analyst Ratings
BofA Securities downgraded FibroGen Inc. (NASDAQ: FGEN) to a an Underperform rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for FibroGen Inc. (FGEN) among analysts is Hold. According to current brokerage recommendations, 1 brokerage firm advise that investors sell FGEN, while 5 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 0 others rate it as a “buy”.
What is FGEN’s price target for the next 12 months?
Analysts predict a range of price targets between $2.00 and $37.20, with a median target of $3.00. Taking a look at these predictions, the average price target given by analysts for FibroGen Inc. (FGEN) stock is $11.14.
